Find Academic Supervisors

Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.

• Ubiquitin-Proteasome Pathway
• Proteostasis
• Protein Degradation
• +7 more

Anirban Paul is an Associate Professor in the Department of Neuroscience and Experimental Therapeutics at Pennsylvania State University, affiliated with the Penn State Neuroscience Institute. His research focuses on cellular and molecular mechanisms of GABAergic inhibitory circuits, with particular emphasis on interneuron biology and its implications in neurological disorders. Dr. Paul's research spans multiple neuroscience domains, with primary focus on GABAergic inhibitory circuits and interneuron biology. His work investigates how specific neuron subtypes, particularly Chandelier cells and cortical interneurons, contribute to brain function and dysfunction. He has made significant contributions to understanding the role of these cells in schizophrenia, Alzheimer's disease, and other neurological conditions. His research integrates molecular, cellular, and systems-level approaches to uncover fundamental mechanisms of neural circuit assembly, plasticity, and function. Key areas include RNA regulation in neuronal development, transcriptomic subtypes of inhibitory neurons, and cell-type specific vulnerabilities in neurodegenerative diseases. His research portfolio demonstrates consistent productivity with publications spanning from 2003 to 2025, showing an evolving focus from basic molecular neuroscience to translational research in neurological disorders. Recent work emphasizes single-cell analysis techniques and the role of specific interneuron populations in disease mechanisms, particularly in schizophrenia and Alzheimer's disease. His publications appear in high-impact neuroscience journals including Neuron, BMC Biology, and Frontiers in Cellular Neuroscience. Dr. Paul has received the NARSAD Young Investigator Award (2018), recognizing his promising research in neuroscience. His scientific contributions have been supported by multiple competitive grants from prestigious organizations including the National Institute on Aging (NIA) and the Brain and Behavior Research Foundation. He serves as Principal Investigator on multiple active research projects, including two major grants from the National Institute on Aging focused on cell-type specific risk and resilience in Alzheimer's disease and aging (2021-2024 and 2024-2026), as well as previous projects from the Brain and Behavior Research Foundation investigating Chandelier cells in schizophrenia. His research program demonstrates sustained funding and scientific leadership in the field of interneuron biology and its clinical implications.

• Neuroscience
• GABAergic inhibitory circuits
• Interneuron biology
• +5 more

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +5 more

Carmen Bergom, MD, PhD, is an Associate Professor of Radiation Oncology at Washington University School of Medicine (WashU Medicine), where she joined the faculty in 2020. She holds secondary appointments in the Division of Cancer Biology and the Siteman Cancer Center. Her research focuses on leveraging genetic models to improve radiation therapy efficacy while mitigating radiation-induced cardiotoxicity , particularly in breast cancer patients. Key areas include radiation biology , tumor microenvironment , and cardio-oncology . Recent publications highlight her work in genetic mapping of radiation sensitivity (e.g., rat chromosome 3 variants), innovative imaging techniques (e.g., integrin-targeted PET), and clinical trial design for cardiovascular risk stratification. Her laboratory has pioneered the first genetic studies of radiation-induced cardiac dysfunction. Scientific awards include the Michael Fry Research Award (2021) and recognition as a Top Doctor in America (2018, 2019). She serves as Chair of the ASTRO Science Council Scientific Review Panel and co-chair of the Clinical and Experimental Research in Radiation Oncology meeting at ESTRO. Dr. Bergom treats breast cancer patients clinically and mentors students across all levels (undergraduate to postdoctoral). Her work bridges basic research with clinical applications , aiming to develop biomarkers and therapeutic targets for radiation oncology.

• Radiation Oncology
• Breast Cancer
• Tumor Microenvironment
• +5 more

Martin Burke is the May and Ving Lee Professor for Chemical Innovation and Professor of Chemistry at the University of Illinois Urbana-Champaign , with additional appointments in Biochemistry, Biomedical & Translational Sciences, and multiple campus institutes including the Beckman Institute and the Carl R. Woese Institute for Genomic Biology. Education B.S. Johns Hopkins University , 1998 Ph.D. Harvard University , 2003 M.D. Harvard Medical School , 2003 Research Interests Burke’s program centers on molecular prosthetics : the design, synthesis and application of small molecules that replicate or replace missing or dysfunctional proteins. His group pioneered iterative cross-coupling (ICC) using MIDA-protected haloboronic acids to automate the construction of complex natural products and function-oriented small molecules. Current projects target ion-channel replacement in cystic fibrosis, iron-transport restoration in anemia, and non-toxic antifungals that overcome drug resistance. Scientific Awards & Honors National Academy of Medicine (2021) AAAS Fellow (2021) ASCI Member (2021) iCON Award (2019) Mukaiyama Award, Japan (2019) ACS Nobel Laureate Award for Graduate Education (2017) Thieme-IUPAC Prize in Synthetic Organic Chemistry (2014) Elias J. Corey Award (2013) Arthur C. Cope Scholar Award (2011) Research Output & Impact Burke has authored >120 peer-reviewed articles, >30 patents, and his work has been cited >20,000 times. High-impact publications in Nature , Science , and Angewandte Chemie have advanced automated synthesis, molecular prosthetics, and cystic fibrosis therapeutics. Laboratory & Training The Burke Laboratories house a multidisciplinary team of graduate students, post-doctoral researchers, and physician-scientists developing next-generation molecular prosthetics. The group is supported by NIH, NSF, private foundations, and industry partnerships aimed at democratizing molecular innovation.

• Organic Chemistry
• Small-Molecule Synthesis
• Molecular Prosthetics
• +7 more

Dr. Megan Renna is an Assistant Professor in Clinical Psychology at the University of Southern Mississippi. She earned her Ph.D. in Clinical Psychology from Columbia University's Teachers College and completed a postdoctoral fellowship funded by the National Cancer Institute at Ohio State University Comprehensive Cancer Center. Her research focuses on the bidirectional relationship between psychological and physical health, particularly how emotion regulation and negative emotionality contribute to chronic disease risk in breast cancer survivors and healthy adults. Education: Ph.D. in Clinical Psychology (2019) and M.Ph. (2018) from Teachers College, Columbia University Training: Predoctoral internship at Duke University Medical Center Her work bridges clinical psychology, psychophysiology, and behavioral medicine through studies on inflammation, autonomic dysfunction, and cancer survivorship. Recent publications examine metabolic syndrome, smartwatch body composition metrics, and couples' health dynamics. Key research themes include stress reactivity, emotion regulation therapy, and biobehavioral pathways linking mental states to physiological outcomes. Dr. Renna teaches Advanced Psychopathology and can be reached at Megan.Renna@usm.edu. Her methodological expertise spans experimental worry inductions, longitudinal studies, and psychometric scale development, with a focus on reducing distress disorders through emotion regulation interventions.

• Clinical Psychology
• Clinical Health Psychology
• Emotion Regulation
• +6 more

Priya Raman, Ph.D., FCVS, is an Associate Professor of Integrative Medical Sciences at Northeast Ohio Medical University (NEOMED). She holds tenure and serves as Co-Director of the Basic and Translational Biomedicine (BTB) Graduate Program and Chair of the Kent State University-Biomedical Sciences Pharmacology Graduate Program. Her academic roles include teaching in NEOMED’s medical curriculum, focusing on pharmacology, cardiovascular systems, and clinical therapeutics. Raman’s research explores molecular mechanisms linking metabolic disorders (e.g., diabetes, metabolic syndrome) to vascular dysfunction and Alzheimer’s disease, using mouse models and cellular/molecular techniques. She has published extensively on thrombospondin-1, O-GlcNAc signaling, and atherosclerosis pathogenesis. Education: B.Pharm. and M.Pharm. (India), Ph.D. in Pharmacology (University of Louisiana at Monroe). She has over 25 years of postdoctoral and faculty experience, including roles at the Cleveland Clinic and Indiana University School of Medicine. Raman serves on editorial boards for journals like International Journal of Cardiology and Frontiers in Cardiovascular Medicine , and reviews grants for the American Heart Association and NIH. Research focus areas include: (1) Vascular smooth muscle cell phenotypic switching in metabolic diseases, (2) Non-lipid mechanisms of vascular disease in metabolic syndrome, and (3) Interactions between metabolic disorders and neurodegeneration. Her lab employs biochemical assays, mouse models (e.g., ApoE-/-, KKAy), and advanced imaging techniques to study these pathways. Notable recent work includes discovering that O-GlcNAc transferase deletion reduces atherosclerosis in hyperglycemic mice and identifying thrombospondin-1’s role in leptin-driven vascular pathology. She has also linked metabolic syndrome-induced O-GlcNAc deficits to Alzheimer’s-like cognitive impairment in aging mice. Raman is actively involved in interprofessional education and mentoring, directing graduate programs and teaching courses in pharmacology, molecular signaling, and diabetes/vascular disease. Her work bridges basic science and clinical applications, aiming to develop novel therapies for metabolic syndrome-related vascular complications.

• Molecular mechanisms of vascular smooth muscle cell phenotypic switching
• Non-lipid causes of vascular disease in metabolic syndrome
• Mechanistic links between metabolic syndrome, vascular dysfunction, and Alzheimer’s disease
• +3 more

Heather A Anaya, DO , is a Clinical Assistant Professor at the Feinberg School of Medicine, Northwestern University , specializing in Obstetrics and Gynecology with a focus on Maternal-Fetal Medicine . She practices at Northwestern Medicine Central DuPage Hospital and Northwestern Medicine Delnor Hospital , and her clinical work centers on high-risk pregnancies. Education : Doctor of Osteopathic Medicine (DO) from Kirksville College Of Osteopathic Medicine (2004) Training : Residency in Obstetrics and Gynecology at Rush University Medical Center (2008); Fellowship in Maternal-Fetal Medicine at University of Wisconsin Medical School (2011) Her research explores maternal-fetal physiology , particularly disruptions in calcium signaling and nitric oxide production in conditions like preeclampsia and gestational diabetes . She has published on ultrasound techniques for prenatal care and vascular dysfunction in pregnancy complications. Her publications highlight trends in diagnostic imaging for fetal anatomy assessment and molecular mechanisms in placental endothelial function. Key areas include ultrasound methodology , metabolic disorders during pregnancy , and vascular biology . She is board-certified in Obstetrics and Gynecology and Maternal-Fetal Medicine by the American Board of Obstetrics and Gynecology. Her clinical affiliations include Northwestern Medicine hospitals, and she adheres to strict professional integrity policies regarding industry disclosures.

• Obstetrics
• Maternal-Fetal Medicine
• Reproductive Medicine
• +3 more

Masato Kato serves as Professor in the Department of Biochemistry at the University of Texas Southwestern Medical Center since 2020 and concurrently as Team Leader at Japan's National Institutes for Quantum and Radiological Science and Technology. His academic trajectory includes progressive appointments from Assistant Professor (2004-2014) to Associate Professor (2014-2020) at UT Southwestern, with prior postdoctoral training at Harvard Medical School and Nara Institute of Science and Technology. 2020-present: Professor, Department of Biochemistry, UT Southwestern 2020-present: Team Leader, National Institutes for Quantum and Radiological Science and Technology, Japan 2014-2020: Associate Professor, Department of Biochemistry, UT Southwestern 2010-2014: Assistant Professor, Department of Biochemistry and Internal Medicine, UT Southwestern 2004-2010: Assistant Professor, Department of Internal Medicine, UT Southwestern 1999-2004: Postdoctoral Fellow, Ellenberger Lab, Harvard Medical School 1998-1999: Postdoctoral Fellow, Hakoshima Lab, Nara Institute of Science and Technology Dr. Kato's research pioneers the biophysical characterization of protein phase separation, particularly focusing on low-complexity domains (LCDs) in neurodegenerative disease contexts. His work establishes fundamental mechanisms of biomolecular condensate formation, including hydrogel polymerization, liquid-solid transitions, and mutation-induced dysregulation in ALS/FTD. Key contributions demonstrate how C9orf72-encoded poly-dipeptides disrupt nucleocytoplasmic transport and how redox states regulate Ataxin-2 phase behavior, bridging structural biochemistry with pathological mechanisms. Analysis of his 22 publications reveals a cohesive research program centered on LCD-driven phase transitions. The most recent 15 articles (2012-2019) systematically investigate pathological aggregation in neurodegeneration, structural basis of condensate formation, and regulatory mechanisms like phosphorylation and oxidation. This body of work establishes LCDs as central players in both physiological RNA granule assembly and disease-associated solidification, with strong emphasis on C9orf72-related ALS/FTD mechanisms. Dr. Kato maintains active leadership within the McKnight Laboratory at UT Southwestern, where his team employs integrated approaches spanning structural biology, cell biology, and biophysics to dissect phase separation mechanisms. His collaborative network includes prominent neuroscience and biochemistry groups, with co-authorship on key studies in Cell, Science, and PNAS.

• Protein Phase Separation
• Low-Complexity Domains
• RNA Granule Biogenesis
• +3 more

Nida Latif is a Research Fellow in the Department of Internal Medicine at Yale School of Medicine. Her work focuses on understanding coronary microvascular dysfunction and ischemic heart disease in patients with nonobstructive coronary arteries, particularly in women. She is a key contributor to the DISCOVER INOCA multicenter registry, evaluating invasive coronary function testing protocols and diagnostic strategies. Her research integrates clinical, anatomical, and physiological data to improve diagnostic accuracy and patient outcomes. Key areas of investigation include coronary vasoreactivity testing, risk factor analysis in ischemic syndromes, and the impact of diabetes on angina pathophysiology. Latif's publications highlight advancements in coronary flow reserve measurement, comparison of diagnostic modalities (e.g., PET vs thermodilution), and the clinical utility of vessel-specific analysis. Her work emphasizes translational outcomes, bridging basic science insights with clinical practice improvements. While no specific awards are listed, her contributions to high-impact clinical registries and peer-reviewed publications reflect her active role in advancing cardiovascular medicine.

• Cardiovascular Disease
• Coronary Microvascular Dysfunction
• Invasive Coronary Function Testing
• +3 more

Nancy J. Brown, M.D., is the Jean and David W. Wallace Dean of the Yale School of Medicine and holds the C.N.H. Long Professorship in Internal Medicine. Previously, she served as Chair of Vanderbilt Department of Medicine and Physician-in-Chief of Vanderbilt University Medical Center (2010–2020). Her academic career spans over three decades, with leadership roles in clinical care, research, and medical education. Education: MD, Harvard University (1986) AB in Molecular Biophysics and Biochemistry, Yale College (1981) Internship and Residency in Medicine, Vanderbilt University (1989) Fellowship in Clinical Pharmacology, Vanderbilt University (1991) Chief Resident, Vanderbilt University (1992) Research Interests: Dr. Brown’s work focuses on the renin-angiotensin-aldosterone system’s role in cardiovascular disease, hypertension, and thrombosis. Her lab has elucidated mechanisms linking aldosterone, bradykinin, and ACE inhibitors to inflammation, fibrosis, and cardiovascular risk. Current studies explore neprilysin inhibitors in heart failure and incretin-based therapies’ cardiovascular effects. Key Contributions: Identified genetic variants and African ancestry as risk factors for ACE inhibitor-associated angioedema Developed Vanderbilt’s Master of Science in Clinical Investigation program (2000) Advocated for physician-scientist development through leadership roles in NIH councils and professional organizations Recognition: Recipient of the Harriet Dustan Award, August M. Watanabe Prize, and Robert H. Williams Distinguished Chair of Medicine. Elected to the National Academy of Medicine and American Academy of Arts & Sciences. Labs/Teams: Leads the Yale School of Medicine’s cardiovascular research initiatives, focusing on translational studies of RAAS pathways and drug mechanisms.

• Cardiovascular Research
• Hypertension
• Pharmacology
• +5 more

Joseph P. Bressler is an Associate Professor at Johns Hopkins University, jointly affiliated with the Bloomberg School of Public Health and the Krieger School of Arts and Sciences. He is a member of the Department of Environmental Health and Engineering and conducts research at the Kennedy Krieger Institute in Baltimore, Maryland. His work bridges public health, neuroscience, and molecular toxicology, focusing on environmental impacts on brain development. Education: PhD, Rutgers University, 1978 Dr. Bressler’s research centers on neurotoxicology, particularly how environmental pollutants such as lead, cadmium, and aluminum disrupt metal transport systems and affect neurodevelopment. His laboratory investigates the role of iron and other metal transporters at the blood-brain barrier and in glial cells, revealing mechanisms of metal uptake and toxicity. His work has implications for understanding autism, fetal alcohol syndrome, and other neurodevelopmental disorders. His recent publications highlight ongoing research into metal homeostasis, cytotoxicity in cancer and neuronal cell lines, e-cigarette aerosol variability, and epigenetic changes in sex chromosome aneuploidies. The research spans molecular mechanisms, in vitro models, and human health outcomes, demonstrating a multidisciplinary approach to environmental health. Scientific Contributions: Elucidated how lead and cadmium hijack iron transporters to enter the brain Demonstrated aluminum activation of iron uptake pathways in glial cells Investigated flavoring agents like ethyl maltol in enhancing metal toxicity Explored epigenetic and behavioral impacts in rare genetic conditions Dr. Bressler has advised numerous researchers and collaborators across disciplines. His work has been supported by federal and institutional grants, though specific funding details are not provided in the source text. He actively publishes in high-impact toxicology and environmental health journals, with research cited in policy and public health discussions. He leads a research laboratory focused on cellular and molecular mechanisms of neurotoxicity, utilizing in vitro models of the blood-brain barrier, astrocytes, and neuronal cell lines. His team collaborates widely across neuroscience, public health, and environmental engineering domains.

• Neurotoxicology
• Environmental Health Sciences
• Metal Transporters
• +12 more

Dr. Peter L. Latchman serves as a Professor in the Department of Health and Movement Sciences at Southern Connecticut State University. He holds a Doctorate in Applied Physiology from Columbia University and is an Overseas Fellow of the Royal Society of Medicine. His academic career spans decades of research in autonomic cardiovascular regulation with applications to diverse populations including Young adults post-COVID-19 infection Ethnic disparities in baroreflex sensitivity Autonomic dysfunction in obese children Central hemodynamic analysis Recent scholarship focuses on autonomic modulation patterns and their implications for cardiovascular health, while his teaching portfolio encompasses both graduate and undergraduate courses in exercise physiology, cardiac rehabilitation, and medical terminology. Dr. Latchman has delivered presentations at international symposia on topics including Baroreflex sensitivity in African American populations Effects of aerobic capacity on autonomic recovery Vascular physiological assessment techniques Scientific contributions include Overseas Fellowship, Royal Society of Medicine $10,000 grant for cardiovascular assessment in autistic children (2023) He maintains active research collaborations with institutions such as East China Normal University and Hong Kong Baptist University.

• Autonomic Modulation of Cardiovascular Function
• Baroreflex Sensitivity
• Childhood Obesity and Autonomic Function
• +1 more

Dr. Justin Belsky is an Assistant Professor of Emergency Medicine at Yale School of Medicine, serving as the COVID-19 Safety Officer and Co-Director of Resident Research in Emergency Medicine. He holds an MD from Wayne State University School of Medicine (2011) and an MPH from Harvard School of Public Health (2016). His research focuses on sepsis diagnosis and treatment, including biomarkers, clinical trials, and risk stratification tools. He led the Yale site for the VICTAS trial evaluating vitamin C, thiamine, and hydrocortisone in septic shock. Dr. Belsky directs the Yale Emergency Medicine Specimen Biobank, collecting samples from critically ill patients for future research. His awards include the Partners in Excellence Team Award (2016) and an Outstanding Poster Award (2015). He is actively involved in resident research training and clinical guideline adherence studies. Education: MD: Wayne State University School of Medicine (2011) Emergency Medicine Residency: Henry Ford Hospital (2014) Research Fellowship: Massachusetts General Hospital (2016) MPH: Harvard School of Public Health (2016) Research Interests: Early sepsis identification and treatment Biomarker development for critical illness Fluid management strategies in septic shock Micronutrient therapies in sepsis Emergency department quality improvement Recent Work Focus: Fluid resuscitation protocols and guideline adherence Long-term outcomes of sepsis therapies Actin cytoskeleton as a sepsis biomarker Antibiotic timing in sepsis Awards: 2016: Sepsis Care Redesign, Partners in Excellence Team Award 2015: Outstanding Poster Award (Shock Symposium) Grants & Mentorship: Principal investigator for CLOVERS trial (fluid management in sepsis) Co-Director of Yale’s Emergency Medicine Research Training Program Leadership in resident research mentorship and biobank initiatives

• Sepsis
• Infectious Diseases
• Critical Care Medicine
• +3 more

Dr. Christina Leslie is a Research Professor and Member of the Computational & Systems Biology Program at Memorial Sloan Kettering Cancer Center (MSK). She leads an active research laboratory focused on developing computational approaches to understand complex biological systems. Dr. Leslie earned her PhD from the University of California, Berkeley and has established herself as a leading computational biologist in cancer research and immunology. Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center Gerstner Sloan Kettering Graduate School of Biomedical Sciences Dr. Leslie's research focuses on developing novel computational methods to study cellular biological systems from a global and data-driven perspective. Her lab exploits diverse high-throughput functional and genomic data to understand molecular networks underlying fundamental cellular processes, including transcription regulation, pre-mRNA processing, signaling, and post-transcriptional gene silencing. Her algorithmic methods draw heavily on machine learning to build accurate predictive models from noisy and high-dimensional biological data. Key areas of interest include modeling cell-type specific transcriptional programs and dissecting co- and post-transcriptional regulation, particularly microRNA-mediated gene regulation. Analysis of Dr. Leslie's publication record over the last five years reveals a strong focus on computational approaches to cancer genomics, immunology, and epigenetics. Her work bridges multiple disciplines, with a particular emphasis on developing machine learning methods to interpret complex biological data. The publications demonstrate increasing sophistication in integrating multiple data types (genomic, transcriptomic, epigenomic) to understand cancer biology and immune responses. Recent work shows a growing emphasis on single-cell technologies and spatial analysis of tumor microenvironments. Introduction of string kernel methodology for SVM classification of biological sequences Development of algorithms for predictive modeling of gene regulation First systems-level analyses of competition between microRNAs and between target transcripts Dr. Leslie actively mentors numerous graduate students and research associates, with current lab members including Vianne Gao, Alireza Karbalaghareh, Erik Ladewig, and several others. Her lab has received significant research funding to support their work on computational approaches to cancer biology and immunology. The Leslie Lab maintains close collaborations with multiple experimental groups at MSK, facilitating the translation of computational insights into biological understanding. The Leslie Lab operates within the Computational & Systems Biology Program at MSK, with strong ties to both the research and clinical missions of the institution. The lab maintains state-of-the-art computational infrastructure for analyzing large-scale genomic and proteomic datasets and collaborates extensively with wet-lab researchers to validate computational predictions experimentally.

• Computational Biology
• Systems Biology
• Machine Learning
• +7 more